DNAtrix Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

DNAtrix Inc (DNAtrix) is an independent clinical stage, biotechnology company that focuses on the development of oncolytic immunotherapies for cancer. The companys portfolio of pipeline products includes DNX-2401, a modified common cold virus that targets and kills cancer cells selectively; DNX-2440; DNX-2450; and MYX-135. Its pipeline includes viruses armed with potent immunomodulatory molecules to treat cancer. DNAtrix offer products for the treatment of solid tumors, hematological malignancies, and recurrent glioblastoma among others. The company is funded by Morningside Ventures and Mercury Fund, and Cancer Prevention and Research Institute of Texas. It has offices in Texas and California. DNAtrix is headquartered in Houston, Texas, the US.

DNAtrix Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

DNAtrix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
DNAtrix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
DNAtrix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
DNAtrix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
DNAtrix Inc, Medical Devices Deals, 2012 to YTD 2018 9
DNAtrix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
DNAtrix Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
DNAtrix Raises USD20 Million in Series B Financing 11
DNAtrix Raises US$1.5 Million In Venture Financing 12
DNAtrix Secures USD0.84 Million Funding from Mercury Fund 13
DNAtrix Secures USD0.16 Million in Venture Funding 14
DNAtrix Raises US$0.88 Million In Venture Financing 15
DNAtrix Secures USD4.5 Million in Venture Funding 16
Partnerships 17
Merck Enters into Agreement with DNAtrix 17
Merger 18
DNAtrix Merges With VectorLogics 18
Licensing Agreements 19
DNAtrix Enters into Licensing Agreement with University of Florida 19
DNAtrix Inc - Key Competitors 20
DNAtrix Inc - Key Employees 21
DNAtrix Inc - Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Product News 23
11/20/2017: Mechanism of Action Studies for DNAtrixs Oncolytic Virus DNX-2401 Presented at the 2017 Society for Neuro-Oncology Annual Meeting 23
11/13/2017: DNAtrix Virus Expressing T-Cell Co-stimulator OX40L (CD252) Presented at the 2017 Society for Immunotherapy of Cancer Meeting 24
Clinical Trials 25
Jun 01, 2017: DNAtrix to Present Results of DNX-2401 for Recurrent Glioblastoma at ASCO 2017 25
Apr 24, 2017: Precision Intratumoral Delivery of DNX-2401 with the Alcyone MEMS Cannula 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List Of Tables

List of Tables
DNAtrix Inc, Pharmaceuticals & Healthcare, Key Facts 2
DNAtrix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
DNAtrix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
DNAtrix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
DNAtrix Inc, Deals By Therapy Area, 2012 to YTD 2018 8
DNAtrix Inc, Medical Devices Deals, 2012 to YTD 2018 9
DNAtrix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
DNAtrix Raises USD20 Million in Series B Financing 11
DNAtrix Raises US$1.5 Million In Venture Financing 12
DNAtrix Secures USD0.84 Million Funding from Mercury Fund 13
DNAtrix Secures USD0.16 Million in Venture Funding 14
DNAtrix Raises US$0.88 Million In Venture Financing 15
DNAtrix Secures USD4.5 Million in Venture Funding 16
Merck Enters into Agreement with DNAtrix 17
DNAtrix Merges With VectorLogics 18
DNAtrix Enters into Licensing Agreement with University of Florida 19
DNAtrix Inc, Key Competitors 20
DNAtrix Inc, Key Employees 21

List Of Figures

List of Figures
Sensient Technologies Corp, Performance Chart (2013 - 2017) 29
Sensient Technologies Corp, Ratio Charts 35